Elan Corp Plc: (NYSE: ELN)

$12.36

0.32 (2.66%)

Volume 30,236,658

May 23 04:04 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		12.15 - 12.42
	
		52wk Low - High
		9.37 - 14.55
	
		Previous Close
		12.04
	
		Avg. Volume
		7,107,231
	
		Industry
		MED-DRUGS
	
		Market Cap
		7.16 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.93
	
		PE (Forward)
		65.08
	
		Current Year Est.
		0.19
	
		Quarterly Earnings ESP 
		20.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		106 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            65.08
                        
                            PEG Ratio
                            1.67
                        
                            Current Year Est.
                            0.19
                        
                            Current Quarter Estimate
                            0.05
                        
                            Most Accurate Estimate
                            0.06
                        
                            Earnings ESP 
                            20.00%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            -0.38
                        
                            Expected Earnings Growth
                            39.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Elan Corporation, plc is a leading worldwide specialty pharmaceutical company focused on the discovery, development and marketing of        therapeutic products and services in neurology, acute care and pain management and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. The company consists of three operating divisions: Elan Pharmaceuticals, Elan Pharmaceutical Technologies and Elan Pharmaceutical Operations.   
Full ELN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ELN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.05	0.01	0.19	0.29
Number of Estimates	2	2	2	2
Low Estimate	0.04	-0.01	0.12	0.17
High Estimate	0.06	0.04	0.25	NA
Year Ago EPS	-0.05	-0.11	-0.66	0.19
EPS Growth	200.00%	113.64%	128.03%	59.46%

More ELN Estimates

Average Earnings Estimates for ELN

EPS Growth for ELN

Industry Analysis

Name	Symbol	Previous Close
ELAN CP PLC ADR	ELN	12.04
JAZZ PHARMACEUT	JAZZ	61.53
SALIX PHARM-LTD	SLXP	59.47
SANTARUS INC	SNTS	22.28
USANA HLTH SCI	USNA	68.14
CATALYST PHARMA	CPRX	0.85
CELL THERAPEUT	CTIC	1.29
CUBIST PHARM	CBST	56.11
INFINITY PHARMA	INFI	23.12
LANNETT INC	LCI	12.03

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Alkermes Reports Earnings for Q4

May 23, 2013

Elan Provides Strategic Update

May 21, 2013

Elan in Royalty Deal with THRX

May 14, 2013

Spectrum Pharma Reports 1Q Loss

May 14, 2013

Dendreon Narrows 1Q Loss

May 10, 2013

Santarus Beats on Earnings and Revs

May 08, 2013

Positive Data on Forest Combo Drug

May 07, 2013

Elan Narrows Y/Y Loss

Apr 25, 2013

More ELN Zacks Commentary

Financials

EPS TTM	-0.38
Sales	1,203
Net Income	-42
Price/Earnings	NA
Price/Book	10.50
Price/Cash Flow	NA
Price/Sales	5.69

More ELN Financials

News

Alkermes Earnings Beat Estimates, But Outlook Unclear - Investors Business Daily

May 23, 2013

Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021 - Businesswire

May 23, 2013

Elan Corporation, plc's Board of Directors Unanimously Reject Royalty Pharma's Revised Tender Offer - Businesswire

May 23, 2013

Elan Releases Response to Royalty Pharma Announcement - Close-Up Media

May 23, 2013

Elan Reports Proposed Offering in Aggregate Principal Amount of Senior Notes Due 2021 - Close-Up Media

May 23, 2013

Elan Reports Recent Transactions - Close-Up Media

May 23, 2013

Elan Set to Possibly Pullback After Yesterday's Rally of 2.66% - Comtex Smartrend(R)

May 23, 2013

Market Maker Surveillance Report. ELN, BAC, RAD, T, INTC, MSFT, Bearishly Biased Price Friction For Wednesday, May 22nd 2013 - M2

May 23, 2013

See All News Stories on ELN

Broker Recommendations

Current ABR	2.20
ABR (Last Week)	2.20
# of recs in ABR	5
Average Target Price	12.63
Industry Rank by ABR	106 out of 265
Rank in Industry	5 out of 93

More ELN Broker Recommendations

Day Low - High	12.15 - 12.42
52wk Low - High	9.37 - 14.55
Previous Close	12.04
Avg. Volume	7,107,231
Industry	MED-DRUGS
Market Cap	7.16 B
Div - Yield	0.00 - 0.00
Beta	0.93
PE (Forward)	65.08
Current Year Est.	0.19
Quarterly Earnings ESP	20.00%

PE (Forward)	65.08
PEG Ratio	1.67
Current Year Est.	0.19
Current Quarter Estimate	0.05
Most Accurate Estimate	0.06
Earnings ESP	20.00%
Next Earnings Report Date	07-24-2013
EPS Last Year	-0.38
Expected Earnings Growth	39.00%

Username: Password:

Remember me [?]

Elan Corp Plc: (NYSE: ELN)

$12.36

0.32 (2.66%)

Volume 30,236,658

May 23 04:04 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations